Thursday, April 30, 2020 1:30:18 AM
WOW - SOUNDS GOOD REALLY : "....CAPR Key points:
1. 100% efficient for 6 COVID-19 acute respiratory distress syndrome (ARDS)
2. FDA approved it to treat up 20 additional COVID-19 patients. ( the test may finish in one month)
3. CAP-1002 are very efficient --- effect in one to four days and no adverse effect
4. CAP-1002 have demonstrated favorable modulation of various inflammatory cytokins and regular the immune response. Which is the key to cure the later COVID-19 patients.
5, CAP-1002 has applaied to 150 patients which showed it is a novel mechanism of GAME CHANGE help COVID-19
6, Next event: CAP-1002 for Duchenne muscular dystrophy (DMD) data will be publish in mid-May 2002...."
1. 100% efficient for 6 COVID-19 acute respiratory distress syndrome (ARDS)
2. FDA approved it to treat up 20 additional COVID-19 patients. ( the test may finish in one month)
3. CAP-1002 are very efficient --- effect in one to four days and no adverse effect
4. CAP-1002 have demonstrated favorable modulation of various inflammatory cytokins and regular the immune response. Which is the key to cure the later COVID-19 patients.
5, CAP-1002 has applaied to 150 patients which showed it is a novel mechanism of GAME CHANGE help COVID-19
6, Next event: CAP-1002 for Duchenne muscular dystrophy (DMD) data will be publish in mid-May 2002...."
Recent CAPR News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 09:20:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 08:06:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:40:53 PM
- Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12 • GlobeNewswire Inc. • 05/04/2026 08:05:00 PM
- Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting • GlobeNewswire Inc. • 04/22/2026 01:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:17:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 08:31:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 09:00:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/02/2026 08:24:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 12:00:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 12:00:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 12:00:11 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/31/2026 09:24:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/31/2026 08:23:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/31/2026 08:23:03 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/31/2026 08:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/27/2026 11:15:05 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/17/2026 09:00:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 08:01:07 PM
- Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/12/2026 08:01:00 PM
- Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy • GlobeNewswire Inc. • 03/12/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 03:01:36 PM
- Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA • GlobeNewswire Inc. • 03/10/2026 01:25:00 PM
- Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12 • GlobeNewswire Inc. • 03/09/2026 12:30:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/27/2026 12:10:54 AM
